Skip to main content
Erschienen in: Rheumatology International 7/2012

01.07.2012 | Case Report

A case of Degos disease successfully treated with corticosteroid combined with cyclophosphamide

verfasst von: Tomohiro Kameda, Hiroaki Dobashi, Kozo Yoneda, Kentaro Susaki, Toshiya Kuno, Koji Murao, Toshihiko Ishida

Erschienen in: Rheumatology International | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Degos disease is a rare disorder characterized by systemic vasculitis involving various organs. There is no established, effective treatment for the disorder, and its prognosis is still poor. Combination therapy with corticosteroid and cyclophosphamide is considered effective for vasculitides involving the small arteries such as ANCA-associated vasculitis. We present here a 42-year-old man who developed Degos disease over several months, and was successfully treated using combined treatment with corticosteroid and cyclophosphamide.
Literatur
2.
Zurück zum Zitat Zamiri M, Jarrett P, Snow J (2005) Benign cutaneous Degos disease. Int J Dermatol 44:654–656PubMedCrossRef Zamiri M, Jarrett P, Snow J (2005) Benign cutaneous Degos disease. Int J Dermatol 44:654–656PubMedCrossRef
3.
Zurück zum Zitat McFarkand HR (1978) Papulosis atrophicans maligna (Kohlmeier-Degos disease): a disseminated occlusive vasculopathy. Ann Neurol 3:388–392CrossRef McFarkand HR (1978) Papulosis atrophicans maligna (Kohlmeier-Degos disease): a disseminated occlusive vasculopathy. Ann Neurol 3:388–392CrossRef
4.
Zurück zum Zitat Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85PubMed Fauci AS, Haynes BF, Katz P, Wolff SM (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98:76–85PubMed
5.
Zurück zum Zitat Yazici Y (2008) Systemic vasculitis treatment and monitoring update, 2008. Bull NYU Hosp Jt Dis 66(3):228–230PubMed Yazici Y (2008) Systemic vasculitis treatment and monitoring update, 2008. Bull NYU Hosp Jt Dis 66(3):228–230PubMed
6.
Zurück zum Zitat Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K et al (2007) BSR and BHPR guidelines for the management of adult with ANCA associated vasculitis. Rheumatology (Oxford) 46(10):1615–1616CrossRef Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K et al (2007) BSR and BHPR guidelines for the management of adult with ANCA associated vasculitis. Rheumatology (Oxford) 46(10):1615–1616CrossRef
7.
Zurück zum Zitat Kohlmeier W (1941) Multiple Hautnekrosen bei Trombangitis obliterans. Arch Klin Exp Dermatol 181:783–792 Kohlmeier W (1941) Multiple Hautnekrosen bei Trombangitis obliterans. Arch Klin Exp Dermatol 181:783–792
8.
Zurück zum Zitat Dubertret L (1999) Malignant atrophic papulosis (Degos’ disease). In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith AL, Katz SI, Fitzpatrick TB (eds) Dermatology in general medicine, vol 1. McGraw-Hill, New York, pp 1157–1161 Dubertret L (1999) Malignant atrophic papulosis (Degos’ disease). In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith AL, Katz SI, Fitzpatrick TB (eds) Dermatology in general medicine, vol 1. McGraw-Hill, New York, pp 1157–1161
9.
Zurück zum Zitat Ryan TJ (1998) Malignant atrophic papulosis. In: Champion RH, Burton JL, Burns DA, Breathnach SM (eds) Textbook of dermatology, vol 3. Blackwell, London, pp 2216–2217 Ryan TJ (1998) Malignant atrophic papulosis. In: Champion RH, Burton JL, Burns DA, Breathnach SM (eds) Textbook of dermatology, vol 3. Blackwell, London, pp 2216–2217
10.
Zurück zum Zitat Katz SK, Mudd LJ, Roenigk HH (1997) Malignant atrophic papulosis (Degos’ disease) involving three generations of family. J Am Acad Dermatol 37:480–484PubMedCrossRef Katz SK, Mudd LJ, Roenigk HH (1997) Malignant atrophic papulosis (Degos’ disease) involving three generations of family. J Am Acad Dermatol 37:480–484PubMedCrossRef
11.
Zurück zum Zitat Ball E, Newburger A, Ackerman AB (2003) Degos’ disease: a distinctive pattern of disease, chiefly of lupus erythematosus, and not a specific disease per se. Am J Dermatopathol 25(4):308–320PubMedCrossRef Ball E, Newburger A, Ackerman AB (2003) Degos’ disease: a distinctive pattern of disease, chiefly of lupus erythematosus, and not a specific disease per se. Am J Dermatopathol 25(4):308–320PubMedCrossRef
12.
Zurück zum Zitat Heymann WR (2009) Degos disease: considerations for reclassification. J Am Acad Dermatol 61(3):505–506PubMedCrossRef Heymann WR (2009) Degos disease: considerations for reclassification. J Am Acad Dermatol 61(3):505–506PubMedCrossRef
13.
Zurück zum Zitat Howsden SM, Hodge DJ, Herndon JH, Freeman RG (1976) Malignant atrophic papulosis of Degos. Report of a patient who failed response to fibrinolytic therapy. Arch Dermatol 112:1582–1588PubMedCrossRef Howsden SM, Hodge DJ, Herndon JH, Freeman RG (1976) Malignant atrophic papulosis of Degos. Report of a patient who failed response to fibrinolytic therapy. Arch Dermatol 112:1582–1588PubMedCrossRef
14.
Zurück zum Zitat Zhu KJ, Zhou Q, Lin AH, Lu ZM, Cheng H (2007) The use of intravenous immunoglobulin in cutaneous and recurrent perforating intestinal Degos disease (malignant atrophic papulosis). Br J Dermatol 157(1):206–207PubMedCrossRef Zhu KJ, Zhou Q, Lin AH, Lu ZM, Cheng H (2007) The use of intravenous immunoglobulin in cutaneous and recurrent perforating intestinal Degos disease (malignant atrophic papulosis). Br J Dermatol 157(1):206–207PubMedCrossRef
Metadaten
Titel
A case of Degos disease successfully treated with corticosteroid combined with cyclophosphamide
verfasst von
Tomohiro Kameda
Hiroaki Dobashi
Kozo Yoneda
Kentaro Susaki
Toshiya Kuno
Koji Murao
Toshihiko Ishida
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 7/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1436-z

Weitere Artikel der Ausgabe 7/2012

Rheumatology International 7/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.